Breast cancer (invasive) · line 1 · AI + ribociclib (HR+/HER2- metastatic 1L; OS-validated)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-AI-RIBOCICLIB`

ID	`IND-BREAST-HR-POS-MET-1L-CDKI`
Type	Indication
Status	pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-ESMO-BREAST-METASTATIC-2024` `SRC-MONALEESA-2-HORTOBAGYI-2016` `SRC-MONALEESA-3-SLAMON-2018` `SRC-MONALEESA-7-TRIPATHY-2018` `SRC-NCCN-BREAST-2025`

Notes

Workhorse 1L for HR+/HER2- metastatic. Premenopausal patients require ovarian suppression added (LHRH agonist). Ribociclib has best OS data; palbociclib / abemaciclib clinically interchangeable per institutional preference. Switch to fulvestrant + CDK4/6i (or new CDK4/6i) acceptable 2L.

Used By

Algorithms

ALGO-BREAST-1L - ALGO-BREAST-1L

Handbook Chapters

HB-BREAST-HR-POS-HER2-NEG-1L - HR+/HER2- metastatic breast cancer: first-line reasoning

Handbook Questions

HQ-BREAST-HR-POS-1L-001 - HQ-BREAST-HR-POS-1L-001